MRG-001

Phase 2Small molecule

MMedRegen LLC

MRG-001 is one of 130 small molecule programs targeting Wound Healing. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wound HealingActive, not recruiting

HepatitisActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

COVID-19Active, not recruiting

Wound HealingPhase 2

Active, not recruiting

HepatitisPhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

MRG-001

MMedRegen LLC

Phase 2

1 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Nexavar

Bayer

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Singulair

AstraZeneca

Preclinical

1 9

Aimovig

Amgen

Preclinical

1 10

Aldactone

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Hepatitis

NCT06307522

Clinical

Trials by Indication[1]

ARDS1 trial

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Not yet recruiting·MMedRegen LLC·Phase 2·NCT06308926·60 enrolled

Wound Healing1 trial

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Completed·MMedRegen LLC·Phase 2·NCT05844527·10 enrolled

COVID-191 trial

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Unknown status·MMedRegen LLC·Phase 2·NCT04646603·40 enrolled

Amyotrophic Lateral Sclerosis1 trial

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Not yet recruiting·MMedRegen LLC·Phase 2·NCT06315608·10 enrolled

Hepatitis1 trial

MRG-001 in Patients With Alcoholic Hepatitis

Not yet recruiting·MMedRegen LLC·Phase 2·NCT06307522·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MRG-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MRG-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MRG-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MedRegen LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedRegen LLC

MRG-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

ARDS1 trial

Wound Healing1 trial

COVID-191 trial

Amyotrophic Lateral Sclerosis1 trial

Hepatitis1 trial

References

Drug Info

Quick Facts

Related News